Khaled Musallam: Earlier Recognition, Better Outcomes in NTDT
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Advances, adding:
”Pleased to share another new Editorial out today in Blood Advances, a journal of the American Society of Hematology: ‘Too little, too late? The burden of delayed care in NTDT.’
A challenge that remains very real in non-transfusion-dependent thalassemia (NTDT) is delayed recognition, diagnosis, and referral to specialist care, with many patients reaching adulthood having already developed serious morbidities.
A reminder that NTDT is not a mild disease and that earlier recognition, specialist referral, and timely intervention can change its trajectory.”
Title: Too little, too late? The burden of delayed care in NTDT
Authors: Khaled M. Musallam, Thomas D. Coates, Ali T. Taher
Find more posts featuring Khaled Musallam on Hemostasis Today.
-
Sep 11, 2026, 17:29Reyhan Kose Cobanoglu: APS ACTION Registry Study Published in Lupus
-
Sep 11, 2026, 17:14Obi Light Ogbonnia: From Kenya to Global Sickle Cell Advocacy
-
Sep 11, 2026, 17:01EAHAD 2027 Marks 20 Years
-
Sep 11, 2026, 16:54Denise Braendgaard: Reimagining Health Systems Through Collective Action
-
Sep 11, 2026, 16:47Jehad Khamaysa: Budd-Chiari Syndrome as the Initial Presentation of Behçet’s Disease in a 16-Year-Old
-
Sep 11, 2026, 16:44Mostafa Faisal Mohammed Saleh: From HLA Biology to Curative Therapy
-
Sep 11, 2026, 16:38Jim Kaveney: Class I, Level A – Lifestyle is Now the Official Standard in AFib Care
-
Sep 11, 2026, 16:31George Touma: Do We Really Need to Implant Metal in Every High-Bleeding-Risk Patient?
-
Sep 11, 2026, 16:24Yonah S. Tehrani: CDT vs Anticoagulation in Intermediate High Risk PE – The PRAGUE-26 Trial